Merus price target raised to $99 from $90 at Stifel

Stifel analyst Bradley Canino raised the firm’s price target on Merus to $99 from $90 and keeps a Buy rating on the shares. Stifel expects shares to grind higher into year-end as it becomes increasingly clear that Merus is a de-risked multi-billion-dollar oncology opportunity with limited conceivable bear theses, the analyst tells investors in a research note.